NCT03186365View on ClinicalTrials.gov

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Zepatier Oral Product

Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT03186365 - 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis | Biotech Hunter | Biotech Hunter